Posted On: 03/01/2016 10:00:23 AM
Post# of 72447
Wasnt the phase 1 already showing expression of reaction to prurisol with no toxicity ?:
'' is pleased to announce that it has just received notice that the data from its Phase 1 trial of the Company’s anti-psoriasis drug candidate Prurisol™ for the conversion of Prurisol to abacavir indicated “the areas are within passing Bioequivalency limits.” Cellceutix believes it has met the primary endpoints and objectives of the study. Cellceutix is developing Prurisol™ under guidance from the U.S. Food and Drug Administration that a 505(b)(2) designation is an acceptable pathway to expedite development of the compound for treating psoriasis.
'' is pleased to announce that it has just received notice that the data from its Phase 1 trial of the Company’s anti-psoriasis drug candidate Prurisol™ for the conversion of Prurisol to abacavir indicated “the areas are within passing Bioequivalency limits.” Cellceutix believes it has met the primary endpoints and objectives of the study. Cellceutix is developing Prurisol™ under guidance from the U.S. Food and Drug Administration that a 505(b)(2) designation is an acceptable pathway to expedite development of the compound for treating psoriasis.
(0)
(0)
